08.04.16
AbbVie
2Q Revenues:$6.5 billion (+18%)
2Q Earnings: $1.6 billion (+18%)
YTD Revenues: $12.4 billion (+18%)
YTD Earnings: $3.0 billion (+24%)
Comments: HUMIRA sales increased 17% to $4.1 billion in the quarter. IMBRUVICA revenue reached $439 million in the quarter and Viekira sales were $419 million, up 9%. Lupron sales were $219 million, up 10%. Synthroid sales were $188 million, up 1% and Creon sales were $180 million, up 13%. Kaletra sales fell 12% to $146 million. In the quarter, the company received regulatory approvals for VENCLEXTA and ZINBRYTA.
2Q Revenues:$6.5 billion (+18%)
2Q Earnings: $1.6 billion (+18%)
YTD Revenues: $12.4 billion (+18%)
YTD Earnings: $3.0 billion (+24%)
Comments: HUMIRA sales increased 17% to $4.1 billion in the quarter. IMBRUVICA revenue reached $439 million in the quarter and Viekira sales were $419 million, up 9%. Lupron sales were $219 million, up 10%. Synthroid sales were $188 million, up 1% and Creon sales were $180 million, up 13%. Kaletra sales fell 12% to $146 million. In the quarter, the company received regulatory approvals for VENCLEXTA and ZINBRYTA.